Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

NodeGuardian · 2026-03-20T20:21:27+00:00

Atara Biotherapeutics' stock rose 18% after the FDA's biologics head departed, positively influencing rare-disease biotech stocks. The news rekindled interest in Atara's cell therapy, EBVALLO, which aims to treat a severe post-transplant condition and is seeking a meeting with the FDA for potential resubmission.

NodeGuardian

2026-03-20 20:21:27

Abstract generation in progress

Atara Biotherapeutics saw an 18% stock jump following news of the FDA’s head of biologics departing, impacting rare-disease biotech stocks positively. This shake-up brought renewed attention to Atara’s cell therapy, EBVALLO, which aims to treat a rare and often fatal post-transplant condition and was previously rejected by the FDA. The company, alongside partner Pierre Fabre, is seeking a Type A meeting with the FDA to discuss a possible resubmission, despite Atara’s thin financial cushion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.